JP2014518198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518198A5 JP2014518198A5 JP2014513193A JP2014513193A JP2014518198A5 JP 2014518198 A5 JP2014518198 A5 JP 2014518198A5 JP 2014513193 A JP2014513193 A JP 2014513193A JP 2014513193 A JP2014513193 A JP 2014513193A JP 2014518198 A5 JP2014518198 A5 JP 2014518198A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- glu
- set forth
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001413 amino acids Chemical class 0.000 claims 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 2
- 102220638483 Protein PML_K65R_mutation Human genes 0.000 claims 1
- 102220482677 Uncharacterized protein EXOC3-AS1_A61S_mutation Human genes 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102220259319 rs1553651734 Human genes 0.000 claims 1
- 102220122856 rs201556985 Human genes 0.000 claims 1
- 102220036189 rs273585616 Human genes 0.000 claims 1
- 102220040126 rs371657037 Human genes 0.000 claims 1
- 102200080116 rs556297791 Human genes 0.000 claims 1
- 102220041067 rs587778601 Human genes 0.000 claims 1
- 102220088977 rs869312698 Human genes 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168327.2 | 2011-05-31 | ||
| EP11168327 | 2011-05-31 | ||
| US201161492990P | 2011-06-03 | 2011-06-03 | |
| US61/492,990 | 2011-06-03 | ||
| PCT/EP2012/060248 WO2012164021A1 (en) | 2011-05-31 | 2012-05-31 | Il-21 epitope and il-21 ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014518198A JP2014518198A (ja) | 2014-07-28 |
| JP2014518198A5 true JP2014518198A5 (enExample) | 2015-07-16 |
Family
ID=47258396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513193A Withdrawn JP2014518198A (ja) | 2011-05-31 | 2012-05-31 | Ｉｌ−２１のエピトープおよびｉｌ−２１リガンド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140170153A1 (enExample) |
| EP (1) | EP2714198A1 (enExample) |
| JP (1) | JP2014518198A (enExample) |
| CN (1) | CN103702721A (enExample) |
| WO (1) | WO2012164021A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014205501A1 (en) * | 2013-06-27 | 2014-12-31 | Monash University | Il-21 binding proteins and uses thereof |
| AR099625A1 (es) * | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| PL3139948T3 (pl) * | 2014-05-07 | 2020-08-10 | Novo Nordisk A/S | Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21 |
| DK3139948T3 (da) * | 2014-05-07 | 2020-05-25 | Novo Nordisk As | Behandling af type 1 diabetes under anvendelse af glp-1 og anti-il-21 |
| US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| WO2016096858A1 (en) * | 2014-12-19 | 2016-06-23 | Mabtech Ab | Composition, kit and method for inhibition of il-21 mediated activation of human cells |
| CA3083941A1 (en) * | 2017-12-06 | 2019-06-13 | Pandion Therapeutics, Inc. | Il-2 muteins and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998048837A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| JP2007534631A (ja) | 2003-10-28 | 2007-11-29 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用 |
| ITRM20040586A1 (it) * | 2004-11-29 | 2005-02-28 | Giuliani Spa | Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico. |
| JP5322653B2 (ja) | 2005-11-28 | 2013-10-23 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２１アンタゴニスト |
| WO2009047360A1 (en) * | 2007-10-11 | 2009-04-16 | Novo Nordisk A/S | Il-21 antibodies |
| JP5745274B2 (ja) * | 2007-12-07 | 2015-07-08 | ザイモジェネティクス， インコーポレイテッド | 抗ヒトｉｌ−２１モノクローナル抗体 |
| WO2009132821A1 (en) * | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
-
2012
- 2012-05-31 CN CN201280037924.8A patent/CN103702721A/zh not_active Withdrawn
- 2012-05-31 JP JP2014513193A patent/JP2014518198A/ja not_active Withdrawn
- 2012-05-31 US US14/122,572 patent/US20140170153A1/en not_active Abandoned
- 2012-05-31 EP EP12727128.6A patent/EP2714198A1/en not_active Withdrawn
- 2012-05-31 WO PCT/EP2012/060248 patent/WO2012164021A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518198A5 (enExample) | ||
| JP2014506259A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2014205674A5 (enExample) | ||
| JP2011046732A5 (enExample) | ||
| JP2013198490A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| JP2018507220A5 (enExample) | ||
| WO2016207304A3 (en) | Monoclonal anti-il-1racp antibodies | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| JP2011173884A5 (enExample) | ||
| RU2020129387A (ru) | Антитела к pd-1 собак | |
| JP2016508496A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| RU2017114341A (ru) | Антитела к pd-l1, связывающие pd-l1 собаки | |
| JP2015535828A5 (enExample) | ||
| JP2016500673A5 (enExample) | ||
| JP2012524071A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |